Avalo Therapeutics (AVTX) Payables (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Payables data on file, last reported at $356000.0 in Q1 2026.

• Quarterly Payables fell 65.8% year-over-year to $356000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $356000.0 (down 65.8% YoY) and the FY2025 annual result came in at $137000.0, down 78.69% from the prior year.
• Payables grew to $356000.0 in Q1 2026, from $137000.0 in the prior quarter.
• In the past five years, Payables ranged from a high of $14.9 million in Q2 2023 to a low of $137000.0 in Q4 2025.
• A 5-year average of $3.4 million and a median of $1.0 million in 2025 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables soared 586.97% — and 2024, when it plunged 95.6%.
• Tracing AVTX's Payables over 5 years: stood at $8.8 million in 2022, then sank by 94.94% to $446000.0 in 2023, then soared by 44.17% to $643000.0 in 2024, then plunged by 78.69% to $137000.0 in 2025, then jumped by 159.85% to $356000.0 in 2026.
• The last three Payables figures came in at $356000.0 (Q1 2026), $137000.0 (Q4 2025), and $474000.0 (Q3 2025), per Business Quant data.